PLRX vs. ETNB, CNTA, ABVX, SPRY, OPK, BCYC, ZNTL, TNGX, IMNM, and OCUL
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include 89bio (ETNB), Centessa Pharmaceuticals (CNTA), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), OPKO Health (OPK), Bicycle Therapeutics (BCYC), Zentalis Pharmaceuticals (ZNTL), Tango Therapeutics (TNGX), Immunome (IMNM), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation.
97.3% of Pliant Therapeutics shares are owned by institutional investors. 2.8% of 89bio shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Pliant Therapeutics' return on equity of -34.76% beat 89bio's return on equity.
In the previous week, 89bio had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for 89bio and 4 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.17 beat 89bio's score of 1.12 indicating that 89bio is being referred to more favorably in the media.
89bio has higher earnings, but lower revenue than Pliant Therapeutics.
89bio has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
89bio received 35 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 71.11% of users gave Pliant Therapeutics an outperform vote while only 63.06% of users gave 89bio an outperform vote.
89bio currently has a consensus price target of $28.14, indicating a potential upside of 238.26%. Pliant Therapeutics has a consensus price target of $45.38, indicating a potential upside of 252.29%. Given 89bio's stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than 89bio.
Summary
Pliant Therapeutics beats 89bio on 8 of the 14 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
